ENFORCER

Serial Number 88461039
Registration 5981450
700

Registration Progress

Application Filed
Jun 5, 2019
Under Examination
Approved for Publication
Nov 26, 2019
Published for Opposition
Nov 26, 2019
Registered
Feb 11, 2020

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2020-02-11)
Due: Feb 11, 2026 97 days

Trademark Image

ENFORCER

Basic Information

Serial Number
88461039
Registration Number
5981450
Filing Date
June 5, 2019
Registration Date
February 11, 2020
Published for Opposition
November 26, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Feb 11, 2020
Registration
Registered
Classes
005 042

Rights Holder

INCYTE HOLDINGS CORPORATION

03
Address
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803

Ownership History

MorphoSys AG

Original Applicant
99
Planegg DE

MorphoSys AG

Owner at Publication
99
Planegg DE

MorphoSys AG

Original Registrant
99
Planegg DE

INCYTE HOLDINGS CORPORATION

New Owner After Registration #1
03
WILMINGTON, DE

Legal Representation

Attorney
Frances M. Jagla

USPTO Deadlines

Next Deadline
97 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-02-11)
Due Date
February 11, 2026
Grace Period Ends
August 11, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

28 events
Date Code Type Description Documents
Feb 11, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jun 17, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 17, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 17, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jun 17, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 17, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
May 1, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Apr 24, 2024 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Feb 11, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 26, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 26, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 6, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 17, 2019 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Oct 11, 2019 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Oct 7, 2019 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 13, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 13, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 10, 2019 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Sep 3, 2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Sep 3, 2019 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Sep 3, 2019 CNSL R SUSPENSION LETTER WRITTEN Loading...
Aug 29, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 29, 2019 ALIE A ASSIGNED TO LIE Loading...
Aug 29, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 26, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 21, 2019 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Jun 19, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 8, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; vaccine preparations; antibodies sold as an ingredient of pharmaceuticals for the treatment of treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies for use in the production of active ingredients of pharmaceuticals and vaccines; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis
Class 042
Research and development in the pharmaceutical and biotechnology fields; research and development of medicines; scientific and technological services and research and design services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; providing medical and scientific research information in the field of pharmaceuticals; Research and development services in the field of antibodies

Classification

International Classes
005 042